Study of the ClariFix Cryoablation Device in Patients with Chronic Rhinitis - New Zealand
Safety and Efficacy Study of the ClariFix Cryoablation Device in Patients with Chronic Rhinitis
Arrinex, Inc.
30 participants
Nov 1, 2016
Interventional
Conditions
Summary
Prior studies have shown that cryoablation in the nose improves nasal symptoms in patients with chronic rhinitis. This study is a prospective, non-randomized clinical study to assess the safety and effectiveness of the ClariFix Cryoablation Device when used to ablate unwanted tissue in the nose of patients with chronic rhinitis.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The intervention consists of cryoablation in the nasal passageway using a new cryosurgical device called the ClariFix Device. The ClariFix Device circulates liquid nitrous oxide through a closed-tip cryoprobe, where it is allowed to expand through a fine annular space. The transformation of the liquid into gas extracts heat from the surrounding areas by the Joule-Thompson effect. Either one or two treatments are delivered in each nasal cavity under endoscopic visualization, for a total of two to four treatments per patient. The treatment is delivered under local anesthesia. The total procedure time is approximately 30 minutes. The study procedure is performed only once per patient; there are no repeat procedures.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12614000468628